ClinicalTrials.gg
CompletedNCT06281743LSTPedSurveyUpdated Oct 9, 2026

Attitudes to Decisions to Withdraw or Withhold Life-sustaining Treatments in Critically Ill Children

An observational study in Pediatric Disorder, Critical Illness and Ethics, Narrative, sponsored by Göteborg University. Completed at 1 site in Sweden. Open to participants aged 1 Year to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Göteborg University · Observational

How we know

Updated Oct 9, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
1 Year to 100 Years
Sex
All
01

Study summary

The aim of this study is to investigate attitudes on decisions to withdraw or withhold life-sustaining treatments in critically ill children in Swedish intensive care units. This is a survey among pediatric critical care physicians.

Read the detailed description

Sometimes, the best course of action for a patient is not to receive as much medical care as possible, but rather to prioritize other values. Making a decision to adjust the strategy and goals of care in this manner is referred to as a decision at the breaking point. A breaking point decision often involves decisions about treatment limitations. Treatment limitations in intensive care usually entail decisions to withhold or withdraw one or more life-sustaining treatments. Several events in Swedish society over the past decades may have influenced physicians' attitudes towards making decisions about withdrawing and withholding life-sustaining treatment. In 2009, a pediatric critical care physician was arrested for suspected manslaughter of a child in connection with the termination of intensive care. This initiated a protracted legal process in which the physician was acquitted but suffered significant personal harm due to false accusations. In 2011, the National Board of Health and Welfare issued updated regulations regarding life-sustaining treatments, followed by interpretations in guidelines and strategic documents in subsequent years. In 2020, the opportunity to donate organs was introduced not only after brain death diagnosis but also after circulatory arrest. The coronavirus infectious disease 2019 (COVID-19) pandemic emerged the same year. Sweden faced the threat of having to terminate intensive care not only for the patient's benefit but also due to resource constraints in intensive care. In 2019, a survey was conducted on end-of-life care decisions and practices from the perspective of personnel in pediatric intensive care in large parts of Europe. Sweden was not represented. The investigators are aware that Sweden stands out regarding socio-cultural values (http://www.worldvaluessurvey.org/). Since this has not been studied in Sweden before, and Sweden has a unique position regarding both traditional culture and an individual-centred societal view, it would be exciting to study the attitudes of physicians in Swedish intensive care units.

The investigators intend to map the attitudes of intensive care physicians regarding decisions to withhold/ and withdraw life-sustaining treatment in children within Swedish intensive care using an electronic survey. The method will be reported according to the checklist for reporting results of internet e-surveys (CHERRIES) checklist for web surveys. The survey will be explicitly designed for this study, incorporating a combination of new questions and questions previously used in similar surveys in other parts of Europe. The survey will be validated by a small group with expertise in the study subject and experience in survey research. Validity will be further confirmed through the calculation of Cronbach's alpha between the previously used questions and the new ones. Subsequently, a naive small test group will answer the survey and provide comments. Intensive care units with 10 or more instances of pediatric care visits lasting over 48 hours in 2023 will be selected. Data collection will occur by distributing a link to the web survey via email through a network of clinic managers at the selected intensive care units. It will be an open survey without control for duplicate responses and with a convenience sample. The survey introduction will provide information about the purpose of the study and how respondents' answers will be handled according to the General Data Protection Regulation (GDPR). Respondents will then confirm that they have understood the information before completing the survey. The response rate will be calculated as the proportion of completed surveys compared to the number of unique email addresses to which the survey link was sent. No checks for contradictory responses or incomplete surveys will be conducted before the respondent submits the survey. Incomplete surveys and surveys that take disproportionately long to complete will be analyzed. No propensity score matching or other weighting for differences will be performed. Data analysis will involve descriptive statistics, focusing on identifying correlations between respondents' attitudes toward withholding or withdrawing decisions, their clinical experiences, and any influential factors such as theoretical educational needs.

02

Conditions studied

  • Pediatric Disorder
  • Critical Illness
  • Ethics, Narrative
03

In context

Critical Illness

1,787 studies on the registry are indexed under Critical Illness; 445 are open to participants now.

This study's enrollment of 100 is below the median of 140 across 816 observational studies indexed under Critical Illness.

Browse Critical Illness studies →

Lead sponsor

Göteborg University is the lead sponsor of 272 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Please

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Critical care physicians working with critically ill children in Swedish intensive care units

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (actual)
Patient registry
No

Interventions

  • OtherSurvey

    A web based survey is sent out to pediatric critical care physicians

06

What researchers measure

Primary outcomes

  1. Attitudes and experiences -questionnaire

    Attitudes on decisions to withdraw or withhold life sustaining treatments in critically ill children in Swedish intensive care units. A questionnaire.

    Time frame: 2024-2026

07

Study locations

1 site
  • Sahlgrenska University Hospital
    Gothenburg, Sweden 41345, Sweden
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Oct 2026, 30 months.

Of 441 non-industry observational studies under Critical Illness, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's 30 months is above that.

Counting every sponsor, half of 444 studies reached it within 23 months; a quarter within 12 and three quarters within 46.

Critical Illness covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Dec 2026 → Oct 2026 and completion Dec 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2024
First posted
Feb 28, 2024
StartActual
Apr 1, 2024
Primary completionActual
Oct 5, 2026was Dec 2026
CompletionActual
Oct 5, 2026was Dec 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 9, 2026
Primary completion
Dec 2026→Oct 5, 2026 (actual)
Oct 9, 2026
Study completion
Dec 2026→Oct 5, 2026 (actual)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Active, not recruiting→Completed
    Primary completion Dec 2026→Oct 5, 2026 (now actual)
    Study completion Dec 2026→Oct 5, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06281743
Responsible party
Sponsor
First posted
Feb 28, 2024
Start date
Apr 1, 2024
Primary completion
Oct 5, 2026
Completion
Oct 5, 2026
Last update
Oct 9, 2026

Study contacts

Linda Block, PhD
principal investigator · Göteborg University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion